INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Freeport-McMoran Inc. of Class Action Lawsuit and Upcoming Deadlines - FCX

NEW YORK, November 18, 2025 (ACCESSWIRE) Pomerantz LLP announces that a class action lawsuit has been filed against Freeport-McMoran Inc. (“Freeport” or the “Company”) (NYSE: FCX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Freeport and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until January 12, 2026 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Freeport securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.         

[Click here for information about joining the class action]

On September 9, 2025, Freeport issued a press release announcing the suspension of mining activities at its Grasberg Block Cave operation in Indonesia, after “a large flow of wet material from a production drawpoint . . . blocked access to certain areas within the mine,” trapping seven workers.  The press release further stated that mining operations in the area “have been temporarily suspended to prioritize the safe evacuation of the . . . workers.” 

On this news, Freeport’s stock price fell $2.80 per share, or 5.99%, to close at $43.87 per share on September 9, 2025. 

Then, on September 24, 2025, Freeport provided an update on the incident, reporting that two of the seven workers were “fatally injured” and that the remaining five workers “remain missing.”  The press release further stated that mining operations in the area remained suspended. 

On this news, Freeport’s stock price fell $7.69 per share, or 16.95%, to close at $37.67 per share on September 24, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Perrigo Company plc of Class Action Lawsuit and Upcoming Deadlines - PRGO

NEW YORK, November 18, 2025 (ACCESSWIRE) Pomerantz LLP announces that a class action lawsuit has been filed against Perrigo Company plc (“Perrigo” or the “Company”) (NYSE: PRGO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Perrigo and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until January 16, 2026 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Perrigo securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.         

[Click here for information about joining the class action]

On February 27, 2024, Perrigo reported fiscal year 2023 earnings, revealing significant acquisition and integration-related charges, including a purported one-time cash cost of an additional $35 million to $45 million for remediations to address production and facility issues in its infant formula business.  The Company also disclosed a 50% decline in earnings per share compared to the prior year due to infant formula remediation actions. 

On this news, Perrigo’s stock price fell $4.87 per share, or 15.14%, to close at $27.30 per share on February 27, 2024. 

Then, on May 7, 2024, Perrigo released earnings for the first quarter ended March 30, 2024, revealing the significant negative impact of Perrigo’s costly actions to augment and strengthen its infant formula business. 

On this news, Perrigo’s stock price fell $3.28 per share, or 9.8%, to close at $30.15 on May 7, 2024. 

Then, on August 6, 2025, Perrigo issued a press release announcing earnings for the second quarter ended June 28, 2025, revealing the Company’s adjusted gross profit decreased $30 million, or 6.9%, due in part to “production variability in infant formula, leading to an increase in product scrap in the quarter.” 

                On this news, Perrigo’s stock price fell $3.01 per share, or 11.31%, to close at $23.61 per share on August 6, 2025.

Finally, on November 5, 2025, Perrigo issued a press release, announcing the Company “is initiating a strategic review of its infant formula business” including a “a full range of alternatives.”  The press release revealed Perrigo is “reassessing the Company’s previously announced investment in this business of $240 million.” 

On this news, Perrigo’s stock price fell $5.09 per share, or 25.2%, to close at $15.10 per share on November 5, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gauzy Ltd. - GAUZ

NEW YORK, November 18, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Gauzy Ltd. (“Gauzy” or the “Company”) (NASDAQ: GAUZ).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Gauzy and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On November 14, 2025, Gauzy announced that the Company “will not be releasing its financial results for the third quarter of 2025 on November 14 as previously planned.”  The press release explained that “[t]he reason for the delay is that, during a hearing held on November 13, 2025, the Commercial Court of Lyon, France, ordered the commencement of French law insolvency proceedings (‘Redressement Judiciaire’) relating to three subsidiaries of Gauzy located in France.” 

On this news, Gauzy’s stock price fell $1.35 per share, or 33.58%, to close at $2.67 per share on November 14, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL

NEW YORK, November 18, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Anavex Life Sciences Corp.  (“Anavex” or the “Company”) (NASDAQ: AVXL).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Anavex and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On November 14, 2025, Anavex issued a press release announcing that “[t]he Company was informed by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of a negative trend vote on the Marketing Authorisation Application (MAA) for blarcamesine following its CHMP oral explanation.” 

On this news, Anavex’s stock price fell $2.05 per share, or 35.94%, to close at $3.65 per share on November 14, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Primo Brands Corporation of Class Action Lawsuit and Upcoming Deadlines - PRMB

NEW YORK, November 13, 2025 (ACCESSWIRE) Pomerantz LLP announces that a class action lawsuit has been filed against Primo Brands Corporation (“Primo Brands” or the “Company”) (NYSE: PRMB). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Primo Brands and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until January 12, 2026 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Primo Brands securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.         

[Click here for information about joining the class action]

On June 17, 2024, Primo Water Corporation (“Primo Water”) announced entry into a merger agreement (the “Merger”) with an affiliate of BlueTriton Brands, Inc. (“BlueTriton”).  The two companies touted the synergies of the Merger, stating that the combined company was expected to have “significant financial and operating leverage” and “enhanced distribution capabilities” which would position it “for sustained long-term growth.”  On November 8, 2024, the companies announced the completion of the Merger and the formation of the combined entity, Primo Brands. 

On August 7, 2025, Primo Brands announced its financial results for the second quarter of 2025.  On an accompanying earnings call, Chief Executive Officer Robbert Rietbroek acknowledged that “[t]he speed by which we closed facilities and reduced headcount led to disruptions in product supply, delivery, and service.” 

Following these disclosures, Primo Brands’ stock price fell $2.41 per share, or 9.13%, to close at $24.00 per share on August 7, 2025. 

Then, on November 6, 2025, Primo Brands announced Rietbroek’s departure as CEO and disclosed that the Company was drastically reducing its full year 2025 net sales and adjusted EBITDA guidance.  During a corresponding earnings call, Primo Brands’ new CEO Eric Foss admitted that the Company “probably moved too far too fast on some of the various integration work streams” and that “[t]here’s no doubt that speed impacted our ability to get through a lot of the warehouse closures and route realignment without disruption.”  Foss further revealed that Primo Brands had experienced “customer service issues” as well as “integration issues related to the technology move over.” 

On this news, Primo Brands’ stock price fell $8.20 per share, or 36.19%, over the following two trading sessions, closing at $14.46 per share on November 7, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Telix Pharmaceuticals Limited of Class Action Lawsuit and Upcoming Deadlines - TLX

NEW YORK, November 11, 2025 (ACCESSWIRE) Pomerantz LLP announces that a class action lawsuit has been filed against Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Telix and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until January 9, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Telix securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.         

[Click here for information about joining the class action]

On July 22, 2025, Telix disclosed receipt of a subpoena from the U.S. Securities and Exchange Commission, “seeking various documents and information primarily relating to the Company’s disclosures regarding the development of the Company’s prostate cancer therapeutic candidates.” 

On this news, Telix’s American Depositary Receipt (“ADR”) price fell $1.70 per ADR, or 10.44%, to close at $14.58 per ADR on July 23, 2025. 

Then, on August 28, 2025, Telix issued a press release “announc[ing] that it has received a Complete Response Letter (CRL) from the United States (U.S.) Food and Drug Administration (FDA) for the Biologics License Application (BLA) for TLX250-CDx (Zircaix®, 89Zr-DFO-girentuximab), an investigational PET agent for the diagnosis and characterization of renal masses as clear cell renal cell carcinoma (ccRCC).”  Telix’s press release stated, in relevant part: “The CRL identifies deficiencies relating to the Chemistry, Manufacturing, and Controls (CMC) package.  The FDA has requested additional data to establish comparability between the drug product used in the ZIRCON Phase 3 clinical trial and the scaled-up manufacturing process intended for commercial use.  Additionally, the FDA has documented notices of deficiency (Form 483) issued to two third-party manufacturing and supply chain partners that will require remediation prior to resubmission.” 

On this news, Telix’s ADR price fell $3.45 per ADR, or 18.75%, to close at $14.95 per ADR on August 28, 2025. 

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Inspire Medical Systems, Inc. of Class Action Lawsuit and Upcoming Deadlines - INSP

NEW YORK, November 7, 2025 (ACCESSWIRE) Pomerantz LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (“Inspire” or the “Company”) (NYSE: INSP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

The class action concerns whether Inspire and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until January 5, 2026 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Inspire securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.          

[Click here for information about joining the class action] 

On August 4, 2025, Inspire disclosed that the launch of Inspire V, the Company’s new sleep apnea device, was facing an “elongated timeframe” due to a number of previously undisclosed headwinds.  First, “many centers did not complete the training, contracting and onboarding criteria required prior to the purchase and implant of Inspire V.”   Inspire also disclosed that, although Inspire V’s CPT code had been approved for Medicare patients, “software updates for claims submissions and processing did not take effect until July 1,” which meant that “implanting centers would not be able to bill for those procedures until July 1.”  As a result, many treatment centers simply chose to continue treating with the Inspire IV device until then.  Finally, investors also learned for the first time that excess inventory was also negatively impacting the Inspire V rollout.  As a result of the foregoing issues, Inspire reduced its earnings guidance by more than 80%, from a range of $2.20 to $2.30 per share to just $0.40 to $0.50 per share.   

On this news, Inspire’s stock price fell $42.04 per share, or more than 32%, to close at $87.91 per share on August 5, 2025.  

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. 

Attorney advertising.  Prior results do not guarantee similar outcomes.    

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Six Flags Entertainment Corporation of Class Action Lawsuit and Upcoming Deadlines - FUN

NEW YORK, November 7, 2025 (ACCESSWIRE) Pomerantz LLP announces that a class action lawsuit has been filed against Six Flags Entertainment Corporation (“Six Flags” or the “Company”) (NYSE: FUN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Six Flags and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until January 5, 2026 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Six Flags securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.         

[Click here for information about joining the class action]

On July 1, 2024, Six Flags’ corporate predecessor merged with Cedar Fair, L.P. (“Cedar Fair”) to create North America’s largest regional amusement park operator, with a property portfolio of approximately 40 amusement parks and water parks, along with several resort properties.  The combined entity, named Six Flags Entertainment Corporation, listed its shares on the New York Stock Exchange under the ticker symbol “FUN.”  Following the merger, Six Flags consistently reported poor financial and operational results, revealing that Six Flags’ corporate predecessor had for years deferred or foregone basic park maintenance, operational improvements, infrastructure repairs, and ride design and development updates, necessitating a massive capital infusion.  On the July 1, 2024 closing date of the merger, Six Flags stock traded above $55.00 per share. 

Following the merger, the price of Six Flags stock fell as low as $20 per share, representing a decline of nearly 64%.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in CarMax, Inc. of Class Action Lawsuit and Upcoming Deadlines - KMX

NEW YORK, November 5, 2025 (ACCESSWIRE) Pomerantz LLP announces that a class action lawsuit has been filed against CarMax, Inc. (“CarMax” or the “Company”) (NYSE: KMX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether CarMax and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until January 2, 2026 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired CarMax securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.         

[Click here for information about joining the class action]

On September 25, 2025, CarMax issued a press release reporting its financial results for the second quarter of its 2026 fiscal year.  CarMax reported earnings per share (“EPS”) of only $0.64 on $6.6 billion in sales, falling well short of consensus estimates of EPS of $1.03 on $7 billion in sales.  CarMax’s Chief Executive Officer described the quarter as “challenging” and said that the Company would cut selling, general and administrative spending by $150 million over the next 18 months. 

On this news, CarMax’s stock price fell $11.50 per share, or 20.07%, to close at $45.60 per share on September 25, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Synopsys, Inc. of Class Action Lawsuit and Upcoming Deadlines - SNPS

NEW YORK, November 5, 2025 (ACCESSWIRE) Pomerantz LLP announces that a class action lawsuit has been filed against Synopsys, Inc. (“Synopsys” or the “Company”) (NASDAQ: SNPS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Synopsys and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until December 30, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Synopsys securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.         

[Click here for information about joining the class action]

On September 9, 2025, Synopsys released its third quarter 2025 financial results, revealing the Company’s “IP business underperformed expectations.”  The Company reported quarterly revenue of $1.740 billion, missing its prior guidance of between $1.755 billion and $1.785 billion, and reported net income of $242.5 million, a 43% year-over-year decline from $425.9 million reported for third quarter 2024.  Moreover, the Company reported its Design IP segment accounted for approximately 25% of revenue and came in at $426.6 million, a 7.7% decline year-over-year. Finally, management provided guidance which implied that Design IP revenues will decline by at least 5% on a full-year basis in fiscal 2025. 

On this news, Synopsys’s stock price fell $216.59 per share, or 35.84%, to close at $387.78 per share on September 10, 2025. 

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Avantor, Inc. of Class Action Lawsuit and Upcoming Deadlines - AVTR

NEW YORK, November 4, 2025 (ACCESSWIRE) Pomerantz LLP announces that a class action lawsuit has been filed against Avantor, Inc. (“Avantor” or the “Company”) (NYSE: AVTR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Avantor and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until December 29, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Avantor securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.         

[Click here for information about joining the class action]

On April 25, 2025, Avantor reported disappointing first quarter 2025 financial results, cut its guidance for 2025, and announced that Michael Stubblefield would be stepping down from his roles as President and Chief Executive Officer.  Avantor’s management attributed its weak performance and outlook to “the impact of increased competitive intensity.” 

On this news, Avantor’s stock price fell $2.57 per share, or 16.5%, to close at $12.93 per share on April 25, 2025. 

Then, on August 1, 2025, Avantor reported disappointing second quarter 2025 financial results, including a year-over-year decrease in net sales, and further reduced the Company’s 2025 guidance—now projecting organic revenue growth of -2% to 0%.  Avantor’s management again attributed the Company’s lackluster results and outlook to “increased competitive intensity” and further admitted that Avantor did not expect the competitive environment to materially improve in the remainder of 2025. 

On this news, Avantor’s stock price fell $2.08 per share, or 15.48%, to close at $11.36 per share on August 1, 2025. 

Then, on October 29, 2025, Avantor reported weak third quarter 2025 financial results, including -5% organic revenue growth and a net loss of $712 million, which management primarily attributed to a non-cash goodwill impairment charge of $785 million.  Avantor’s management said that the impairment charge was necessary due in part to “competitive pressures” that had “meaningfully impacted” Avantor’s margins and further disclosed that the Company had lost several large accounts. 

On this news, Avantor’s stock price fell $3.50 per share, or 23.21%, to close at $11.58 per share on October 29, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Live Oak Bancshares, Inc. - LOB

NEW YORK, November 14, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of Live Oak Bancshares, Inc. (“Live Oak” or the “Company”) (NYSE: LOB).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Live Oak and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On November 12, 2025, Live Oak disclosed in a filing with the U.S. Securities and Exchange Commission that “the Company will amend its 2024 Annual Report on Form 10-K . . . and the Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2025 and June 30, 2025, respectively . . . to restate the Consolidated Financial Statements for each of the periods included in those filings in order to restate the Statements of Cash Flows and related notes[.]”  Live Oak said that “an error was identified in the classification of cash flows between operating and investing activities associated with the proceeds received from the sale of loan participations and the related supplemental disclosures of non-cash operating, investing and financing activities related to these loans” and that “given the relative size of the misclassification . . . management concluded the misclassifications are material.”  Live Oak further stated “that a material weakness exists in the Company’s internal control over financial reporting” and that the Company’s previous statements for the periods at issue “should no longer be relied upon.” 

On this news, Live Oak’s stock price fell $0.80 per share, or 2.49%, to close at $31.29 per share on November 13, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PetMed Express, Inc. - PETS

NEW YORK, November 14, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of PetMed Express, Inc. (“PetMed” or the “Company”) (NASDAQ: PETS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

The investigation concerns whether PetMed and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On June 10, 2025, PetMed issued a press release “announc[ing] it is delaying the release of the Company’s fourth quarter and fiscal year 2025 earnings release and subsequent conference call, which had been scheduled for June 10, 2025, because the Company requires additional time to complete the year-end audit process.” 

On this news, PetMed’s stock price fell $0.47 per share, or 11.22%, to close at $3.72 per share on June 11, 2025. 

Then, on July 1, 2025, PetMed announced a delay in the filing of its Annual Report for its 2025 fiscal year, citing, among other things, an internal investigation into revenue recognition. 

On this news, PetMed’s stock price fell $0.05 per share, or 1.51%, to close at $3.27 per share on July 1, 2025. 

Then, on November 12, 2025, PetMed disclosed that it was unable to timely file its quarterly report for the third quarter of 2025 “without unreasonable effort or expense.”  PetMed said that “the Company requires additional time to first complete and file with the SEC its Quarterly Report on Form 10-Q for the prior quarterly period ended June 30, 2025, which has been delayed due to the now-completed previously disclosed investigation by the Company’s Audit Committee.” 

On this news, PetMed’s stock price fell $0.94 per share, or 32.41%, to close at $1.96 per share on November 13, 2025. 

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes. 

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of agilon health, Inc. - AGL

NEW YORK, November 14, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  agilon health, Inc. (“agilon” or the “Company”) (NYSE: AGL).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether agilon and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On August 4, 2025, agilon issued a press release entitled “agilon health Reports Second Quarter 2025 Results.”  Commenting on the results, agilon’s Executive Chair stated that “as we progressed through this transition year, it’s become clear that the industry headwinds are more acute than previously expected[.]” Further, the release announced that the Company was “suspending its previously issued full-year 2025 financial guidance and related assumptions.” 

On this news, agilon’s stock price fell $0.94 per share, or 51.52%, to close at $0.88 per share on August 5, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO

NEW YORK, November 12, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Soleno and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On August 15, 2025, Scorpion Capital (“Scorpion”) published a report that described Soleno’s only product, Vykat XR, as overpriced and potentially unsafe for children. 

Following publication of the Scorpion report, Soleno’s stock price fell $5.73 per share, or 7.41%, to close at $71.63 per share on August 15, 2025. 

Then on November 4, 2025, Soleno revealed during its quarterly earnings call that the discontinuation rate of Vykat XR related to adverse effects was approximately 8% at the end of the third quarter of fiscal 2025.  Soleno’s Chief Executive Officer disclosed during the call that Soleno “did see a disruption in our [Vykat XR] launch trajectory in the wake of a short seller report that was released in mid-August [i.e, the Scorpion report], mostly in the form of a lower number of start forms and increased discontinuations for non-serious adverse events.” 

 On this news, Soleno’s stock price fell $16.98 per share, or 26.59%, to close at $46.87 per share on November 5, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of VirTra, Inc. - VTSI

NEW YORK, November 12, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  VirTra, Inc. (“VirTra” or the “Company”) (NASDAQ: VTSI).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether VirTra and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On November 10, 2025, VirTra issued a press release reporting its financial results for the third quarter of 2025.  Among other items, VirTra reported GAAP earnings per share of -$0.03, missing the consensus estimate by $0.07, and revenue of $5.3 million, missing consensus by $1.69 million.  The Company’s Chief Executive Officer said that the Company “continued to work through a slower federal funding cycle” and that “[t]he timing of federal awards and customer acceptances affected near-term revenue recognition.” 

On this news, Virtra’s stock price fell $0.43 per share, or 7.93%, to close at $4.99 per share on November 11, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bitdeer Technologies Group - BTDR

NEW YORK, November 12, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Bitdeer Technologies Group (“Bitdeer” or the “Company”) (NASDAQ: BTDR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Bitdeer and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On November 10, 2025, Bitdeer issued a press release reporting its unaudited financial results for the third quarter of 2025.  Among other items, Bitdeer reported earnings per share of -$1.28, significantly missing the consensus estimate of -$0.22.  Bitdeer also disclosed that “development of [its] next-generation Seal 04 [ASIC chip] is significantly delayed.” 

On this news, Bitdeer’s stock price fell $2.63 per share, or 14.9%, to close at $15.02 per share on November 11, 2025. 

Then, on November 12, 2025, Bitdeer issues a press release “report[ing] a fire incident at its under-construction facility in Massillon, Ohio.”  According to the press release, “[t]he fire incident occurred on the afternoon of November 11” and “2 of the 26 buildings currently under construction sustained fire damage.” 

On this news, Bitdeer’s stock price fell another $2.83 per share, or 20.3%, to close at $11.11 per share on November 13, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CoreWeave, Inc. - CRWV

NEW YORK, November 12, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  CoreWeave, Inc. (“CoreWeave” or the “Company”) (NASDAQ: CRWV).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether CoreWeave and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On November 10, 2025, CoreWeave issued a press release reporting its financial results for the third quarter of 2025.  Among other items, CoreWeave lowered its 2025 guidance for capital spending and revenue, citing data center capacity issues. 

On this news, CoreWeave’s stock price fell $17.22 per share, or 16.31%, to close at $88.30 per share on November 11, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Outset Medical, Inc. - OM

NEW YORK, November 12, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Outset Medical, Inc. (“Outset Medical” or the “Company”) (NASDAQ: OM).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Outset Medical and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On November 10, 2025, Outset Medical issued a press release announcing the Company’s financial results for the third quarter of 2025.  Among other items, Outset Medical reported non-GAAP earnings per share of -$0.69, missing consensus estimates by $0.03, and revenue of $29.43 million, missing consensus estimates by $1.27 million.  The Company also revised its revenue outlook for 2025 to a range of $115 million to $120 million, down from a prior range of $122 million to $126 million, stating that “the expected timing to close several large opportunities forecasted for the second half of 2025 has shifted.” 

On this news, Outset Medical’s stock price fell $5.85 per share, or 48.47%, to close at $6.22 per share on November 11, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HelloFresh SE - HELFY; HLFFF

NEW YORK, November 12, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  HelloFresh SE (“HelloFresh” or the “Company”) (OTCMKTS: HELFY; HLFFF).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether HelloFresh and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On November 6, 2025, Grizzly Research published a report alleging, among other things, that HelloFresh’s “business is now in sharp decline, with management seemingly prioritizing self-enrichment at shareholders’ expense.”  Specifically, the report asserts that customer demand has declined while the Company’s Chief Executive Officer has “extracted cash by pledging HelloFresh shares as collateral for bank loans” for real estate investments managed by his brother. 

Following publication of the report, HelloFresh’s stock price fell $0.11 per share, or 6.3%, to close at $1.65 per share on November 6, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.